liveBook · Manning

ProtGPT2

As explained in Build AI Drug Discovery Pipelines

ProtGPT2 is an autoregressive generative protein model that produces amino-acid sequences intended to form viable protein structures.

ProtGPT2 is a generative protein model for de novo design: it produces new amino-acid sequences rather than predicting properties of an existing sequence. Its 738-million-parameter GPT-2 decoder generates sequences autoregressively, in one direction. section 13.2.1

ProtGPT2 complements ESM-2, whose bidirectional architecture supports prediction tasks. Experimental validation studies found that ProtGPT2-generated sequences could fold into stable structures despite low similarity to known proteins; this does not establish that every generated sequence will do so. section 13.2.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Summarizes the generation architecture and validation evidence without a generation procedure or implementation.
Examples
Cites experiments in which generated sequences folded into stable structures despite low similarity to known proteins.
What you can do after
Evaluate and understand ProtGPT2’s role and evidence for generating stable protein structures.
How it connects
Contrasts autoregressive generation with ESM-2 and its bidirectional architecture.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.